| NMDAR inhibition-independent antidepressant actions of ketamine metabolites P Zanos, R Moaddel, PJ Morris, P Georgiou, J Fischell, GI Elmer, ... Nature 533 (7604), 481-486, 2016 | 1598 | 2016 |
| Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms P Zanos, R Moaddel, PJ Morris, LM Riggs, JN Highland, P Georgiou, ... Pharmacological reviews 70 (3), 621-660, 2018 | 1161 | 2018 |
| Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma HS Venkatesh, LT Tam, PJ Woo, J Lennon, S Nagaraja, SM Gillespie, J Ni, ... Nature 549 (7673), 533-537, 2017 | 475 | 2017 |
| Palladium-Catalyzed Diastereo-and Enantioselective Synthesis of Substituted Cyclopentanes via a Dynamic Kinetic Asymmetric Formal [3+ 2]-Cycloaddition of Vinyl Cyclopropanes … BM Trost, PJ Morris Angewandte Chemie (International ed. in English) 50 (27), 6167, 2011 | 233 | 2011 |
| Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability J Bonaventura, S Lam, M Carlton, MA Boehm, JL Gomez, O Solís, ... Molecular psychiatry 26 (11), 6704-6722, 2021 | 220 | 2021 |
| Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer VI Sayin, SE LeBoeuf, SX Singh, SM Davidson, D Biancur, BS Guzelhan, ... elife 6, e28083, 2017 | 217 | 2017 |
| Palladium-catalyzed diastereo-and enantioselective formal [3+ 2]-cycloadditions of substituted vinylcyclopropanes BM Trost, PJ Morris, SJ Sprague Journal of the American Chemical Society 134 (42), 17823-17831, 2012 | 209 | 2012 |
| Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ... Science translational medicine 11 (519), eaaw0064, 2019 | 185 | 2019 |
| High-potency ligands for DREADD imaging and activation in rodents and monkeys J Bonaventura, MAG Eldridge, F Hu, JL Gomez, M Sanchez-Soto, ... Nature communications 10 (1), 4627, 2019 | 179 | 2019 |
| Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function EW Lumsden, TA Troppoli, SJ Myers, P Zanos, Y Aracava, J Kehr, J Lovett, ... Proceedings of the National Academy of Sciences 116 (11), 5160-5169, 2019 | 167 | 2019 |
| (2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions P Zanos, JN Highland, BW Stewart, P Georgiou, CE Jenne, J Lovett, ... Proceedings of the National Academy of Sciences 116 (13), 6441-6450, 2019 | 146 | 2019 |
| The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection EA Nelson, J Dyall, T Hoenen, AB Barnes, H Zhou, JY Liang, J Michelotti, ... PLoS neglected tropical diseases 11 (4), e0005540, 2017 | 110 | 2017 |
| Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia PJ Morris, D Medina-Cleghorn, A Heslin, SM King, J Orr, MM Mulvihill, ... ACS chemical biology 9 (5), 1097-1103, 2014 | 109 | 2014 |
| Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites PJ Morris, R Moaddel, P Zanos, CE Moore, T Gould, CA Zarate Jr, ... Organic letters 19 (17), 4572-4575, 2017 | 100 | 2017 |
| (R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses P Zanos, JN Highland, X Liu, TA Troppoli, P Georgiou, J Lovett, PJ Morris, ... British journal of pharmacology 176 (14), 2573-2592, 2019 | 83 | 2019 |
| Hydroxynorketamines: pharmacology and potential therapeutic applications JN Highland, P Zanos, LM Riggs, P Georgiou, SM Clark, PJ Morris, ... Pharmacological reviews 73 (2), 763-791, 2021 | 79 | 2021 |
| Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects R Moaddel, M Shardell, M Khadeer, J Lovett, B Kadriu, S Ravichandran, ... Psychopharmacology 235, 3017-3030, 2018 | 76 | 2018 |
| Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine JN Highland, PJ Morris, P Zanos, J Lovett, S Ghosh, AQ Wang, ... Journal of Psychopharmacology 33 (1), 12-24, 2019 | 63 | 2019 |
| Metabolic profiling reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity MM Mulvihill, DI Benjamin, X Ji, E Le Scolan, SM Louie, A Shieh, ... Chemistry & biology 21 (7), 831-840, 2014 | 60 | 2014 |
| Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures J Dyall, EA Nelson, LE DeWald, R Guha, BJ Hart, H Zhou, E Postnikova, ... The Journal of infectious diseases 218 (suppl_5), S672-S678, 2018 | 59 | 2018 |
